Lite Strategy, Inc. quarterly report, Q3 FY2019

Filing and reporting period

The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter and nine months ended March 31, 2020—not a Lite Strategy, Inc. filing for 2018 Q3 as indicated in the request metadata. Financial amounts below are in U.S. dollars; amounts are rounded to millions unless noted.

Business context

MEI Pharma is a clinical-stage oncology company with four drug candidates: ME-401, voruciclib, ME-344 and pracinostat. Its portfolio includes a Phase 3 pracinostat trial and a Phase 2 ME-401 trial intended to support a potential FDA accelerated-approval application. Revenue primarily reflects license-related research and development services, rather than product sales.

Key financial metrics

At March 31, 2020, cash and cash equivalents were $7.438 million and short-term U.S. government investments were $85.360 million, totaling $92.798 million. Current liabilities were $10.257 million; total liabilities were $22.125 million, including a $9.051 million warrant liability. The balance sheet reports no borrowings or other debt. Stockholders’ equity was $74.498 million. The company reported accumulated losses of $258.8 million.

Changes versus prior comparable periods

• For the nine-month period, revenue fell about 10% to $3.409 million, while operating expenses rose about 6% to $40.584 million and operating loss widened to $37.175 million. Lower Helsinn-related revenue and lower costs for its pracinostat study contributed to the revenue decline; increased ME-401 trial and other R&D costs contributed to higher spending.
• Nine-month net loss rose to $27.540 million from $19.872 million. Results include non-cash gains from revaluing the warrant liability: $8.562 million in 2020 versus $13.274 million in 2019. In the March quarter, the $7.732 million warrant-liability gain helped reduce reported net loss compared with the prior-year quarter, which included a $5.201 million expense.
• Operating cash use increased to $34.854 million from $21.359 million. Financing provided $53.948 million, principally from a December 2019 stock offering that raised $48.5 million net. Shares outstanding increased from 73.545 million at June 30, 2019 to 105.999 million at March 31, 2020.
• Cash and short-term investments increased to $92.798 million from $74.489 million at June 30, 2019. Cash alone decreased to $7.438 million from $9.590 million, as funds were held increasingly in short-term investments.

Outlook, developments and risks

• Management said existing cash and investments were expected to fund operations for at least 12 months from issuance of the statements. This estimate excluded the subsequent ME-401 agreement payment. The company expects operating losses and negative operating cash flows to continue, R&D expenses to increase, and anticipates pursuing additional financing or strategic transactions; future financing is not assured.
• In April 2020, after quarter-end, MEI entered a global ME-401 development and commercialization agreement with Kyowa Kirin Company (KKC). KKC was to pay $100 million in May 2020. The agreement also provides for potential milestones of up to approximately $582.5 million and ex-U.S. royalties. MEI and KKC will share U.S. development costs and profits 50-50; KKC is generally responsible for ex-U.S. development and commercialization costs. Management stated that, giving effect to the agreement, cash and investments would have been $192.8 million.
• COVID-19 was delaying clinical development. TIDAL enrollment continued at a reduced rate and was projected to complete in late 2020, approximately one quarter later than previously expected. Broader risks include trial enrollment and site disruption, supply interruptions, regulatory delays, and potential difficulty raising capital.
• The company entered a new San Diego office lease beginning June 1, 2020 and running through January 2028, with total contractual payments of approximately $11.5 million, plus building expenses. At March 31, the prior office lease had approximately $0.1 million remaining.
• Other potential obligations include Presage development, regulatory and commercial milestones of up to $179 million, and S*Bio milestones of up to $74.5 million, as well as other contingent payments and royalties. No amounts for these potential future payments had been accrued at March 31, 2020. The filing reported no legal proceedings.

Important facts for investors to verify

• Confirm the filing identity and period: the supplied text is MEI Pharma’s March 31, 2020 Form 10-Q, despite the different company and period in the request metadata.
• Verify receipt and timing of KKC’s $100 million payment, and review the agreement’s cost-sharing, milestone and royalty terms; the agreement was signed after quarter-end.
• Track TIDAL enrollment, COVID-related delays, trial results and any changes to the projected timeline or regulatory strategy.
• Assess cash runway against the reported $34.9 million of nine-month operating cash use, expected higher R&D spending, and the new lease commitment.
• Consider potential dilution: 105.999 million common shares were outstanding at March 31, alongside 16.062 million warrants exercisable at $2.54 per share through May 2023 and outstanding stock options.